A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
INC280 will be administered to Japanese patients with advanced soid tumors whose disease has
progressed despite standard therapy or for whom no standard therapy exists. The trial will
assess the safety and tolerability and determine the maximum tolerated dose (MTD) on INC280